Abstract Presentations to Watch at the 2019 Oncology Annual Meeting

Over the next five days, more than 39,000 oncology professionals from around the world will gather at McCormick Place Convention Center in Chicago, Illinois, United States, for the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. During this intensive, 5-day conference, experts across multiple tumor types will discuss state-of-the-art multidisciplinary treatments, topics of controversy, […]

Read More

ctDNA as a Biomarker of Recurrence and Prognosis in Early-Stage CRC

Adjuvant chemotherapy is standard of care for stage III colorectal cancer (CRC) and high-risk stage II CRC. However, decision making for adjuvant therapy is imperfect and based on risk stratification by stage and clinical risk factors. In recent years, circulating tumor DNA (ctDNA) has emerged as a promising noninvasive and dynamic biomarker for monitoring genomic […]

Read More

Role of Alpelisib in HR-Positive PIK3CA-Mutated Advanced Breast Cancer

The standard of care for patients with advanced hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast is endocrine therapy with or without a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor. Despite improvements in patient outcomes, a majority of patients eventually develop acquired resistance to endocrine-based therapy that is challenging to treat. […]

Read More

TMB Predicts Efficacy of Immune Checkpoint Inhibitors in MSI-H mCRC

Microsatellite instability (MSI) is a recognized biomarker of response to immune checkpoint inhibitors (ICIs) in metastatic colorectal cancer (mCRC). However, not all MSI-H patients respond to ICIs, indicating a need for additional biomarkers. In many cancers, tumor mutation burden (TMB) has been shown to be associated with response to immunotherapy, regardless of MSI status or […]

Read More

Presence of Oral HPV After Treatment of HNSCC May Predict Recurrence

An increasing number of patients with oropharyngeal head and neck squamous cell carcinoma (HNSCC) have human papillomavirus (HPV) associated cancer. Although HPV-positive oropharyngeal cancers are generally less aggressive than HPV-negative tumors, around 20% of HPV-positive patients experience cancer progression and death within 5 years. Thus, markers to identify patients at risk for recurrence are needed. […]

Read More

Consensus Molecular Subtypes Predict Outcomes in Patients With mCRC

Adoption of personalized treatment approaches in metastatic colorectal cancer (mCRC), which takes into consideration factors such as primary tumor location, RAS mutation status, and presence of microsatellite instabilities (MSI) for treatment selection, combined with an increased number of treatment options, has led to significant improvements in survival. However, the prognosis of patients with mCRC generally […]

Read More

fda-approvals-june-2019

New FDA Cancer Indications Approved in March and April

Atezolizumab Becomes First Immunotherapy Approved for Breast Cancer. The United States Food and Drug Administration (FDA) granted accelerated approval to the combination of the PD-L1 inhibitor atezolizumab (Tecentriq®, Genentech) and nab-paclitaxel for treatment of patients with PD-L1-positive (PD-L1 stained tumor-infiltrating immune cells [IC] of any intensity covering ≥1% of the tumor area) advanced triple-negative breast […]

Read More

Single-Fraction SBRT Standard of Care for Painful Bone Metastases

Bone is a common metastatic site of advanced cancer. Durable pain control is a major goal of palliative care and important for maintaining quality of life cancer patients. Radiotherapy is the primary method for palliation of painful bone metastases, but there is no consensus regarding optimal dose and fractionation. Although no differences in pain relief […]

Read More